Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.
about
Bromocriptine for type 2 diabetes mellitusColesevelam for type 2 diabetes mellitusDapagliflozin for type 2 diabetes mellitusColesevelam for type 2 diabetes mellitusAntidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetesStandards of medical care in diabetes--2012Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic EffectsWhat's next after metformin? focus on sulphonylurea: add-on or combination therapyRecommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profileStandards of medical care in diabetes--2013Exenatide once weekly: opportunities in the primary care setting.Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Effects of Patient Empowerment Programme (PEP) on clinical outcomes and health service utilization in type 2 diabetes mellitus in primary care: an observational matched cohort study.Standards of medical care in diabetes--2010.Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to declineIncretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes.Safety and efficacy of colesevelam HCl in the treatment of elderly patientsCurrent status of prescription in type 2 diabetic patients from general hospitals in busan.Identifying and meeting the challenges of insulin therapy in type 2 diabetes.Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.Using glycosylated hemoglobin to define the metabolic syndrome in United States adults.Are individuals with diabetes seeing better?: a long-term epidemiological perspective.Renal function and healthcare costs in patients with polycystic kidney disease.Glycemic Control Outcomes by Gender in the Pay-for-Performance System: A Retrospective Database Analysis in Patients with Type 2 Diabetes Mellitus.Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.Defining and achieving treatment success in patients with type 2 diabetes mellitusIncorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trialStandards of medical care in diabetes--2011.Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with diabetes.Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials.Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey.Glycemic control and health disparities in older ethnically diverse underserved adults with diabetes: five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) studyLack of association between 25(OH)D levels and incident type 2 diabetes in older women.The effectiveness of medical assistant health coaching for low-income patients with uncontrolled diabetes, hypertension, and hyperlipidemia: protocol for a randomized controlled trial and baseline characteristics of the study population.
P2860
Q24201924-AD1CDDB3-0BD3-47BF-8CAD-E1F959E4CBDFQ24202334-0DC97C9D-BFD5-4800-B41B-6760AA3C7897Q24234557-FA31E60F-2D40-4F71-B28B-BB474042A461Q24236703-81D8B4DE-E086-4C73-9F1D-CEE3709F108AQ24629052-469E24E5-FB5B-42F2-94F4-E267228182DDQ24632533-73D0374D-CBA7-4992-B93A-871DEFE2E8A1Q26741423-55F8877A-1B2F-47ED-A11C-1382802ED92CQ26786524-2C7A9030-56D8-48F7-B408-3EAA32C92E31Q27687563-22AFC58D-A5EC-4EFF-9A49-7051F8E0C0C8Q29620309-187CC6CD-481F-4E9D-8569-770CC3720399Q30431639-F6A534FA-41A0-497C-AAAC-B0509CCD0AC1Q33354192-0D174D59-9444-4029-BE90-5C2B32CC90EEQ33553225-18A1747F-BEDE-4830-9E45-D4D5388E2CF7Q33554238-DDCAB2B4-B075-4BFA-9A95-ACA79F886F47Q33556901-EFEB4D5D-80D9-4C91-B6EA-336314CF6523Q33602360-D15F8DA1-A274-43EA-89AF-CCA37785F849Q33652884-D20F7527-067C-401E-9718-FC6EB546F0C2Q33663484-B231A0EA-4E3D-45C6-9E5B-F28A1EC3060DQ33850338-598575B3-FC49-4FE2-8D2E-58B821D3F663Q33863413-FCD10748-7A81-43D9-BEF6-4954027DE6B6Q33890208-ACDA9640-D695-43D6-B9F5-1332516F0C6EQ34016012-B796B579-EA6E-4C48-8AAE-81BA2A753D1CQ34016140-E1BD8B4B-B364-4C92-9799-3328DFDF5822Q34024289-3506CEDF-AFD5-4E6B-984C-864DF48BF90DQ34075500-152A32A2-E575-492A-A733-93F0556BD6AEQ34119263-424E5F5E-05E0-4B96-872B-84A6CEABD5AAQ34124353-16151F75-96FA-40CB-B1B2-454AA963379FQ34139048-0AD5B6BC-8901-4117-87E0-302DC2784E55Q34227891-4AD25AAD-43A7-4064-9BD0-054B13C65AAFQ34264365-335A1500-6A94-4FB2-9587-8FA12D3268CBQ34374314-DA5F3130-065D-4845-87E3-393FB87C5720Q34374336-A09A4663-641F-4A9B-8026-B0C8F5D7F44BQ34421955-AD48276D-ABE6-424A-BB91-C0A73D12A2B6Q34425055-DF12969F-CA53-482A-A914-07279A3F986AQ34453963-03953DB8-C97C-439A-8F7E-123FFBDEB5A6Q34475476-8976286B-C6AE-447F-89EA-3ED985AFAA1EQ34503859-E3D1A422-7779-46C2-A5D0-174576956E05Q34507025-30EF7DC1-3A7E-4A3B-8CF9-FF7C74025BF5Q34583291-82F5C9F2-94EA-4B95-BFDB-E2C730519262Q34596680-2457E7AE-2319-4D1F-9F4D-34452D4A8FD7
P2860
Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Diabetes prevalence and therap ...... e United States, 1999 to 2006.
@en
Diabetes prevalence and therap ...... e United States, 1999 to 2006.
@nl
type
label
Diabetes prevalence and therap ...... e United States, 1999 to 2006.
@en
Diabetes prevalence and therap ...... e United States, 1999 to 2006.
@nl
prefLabel
Diabetes prevalence and therap ...... e United States, 1999 to 2006.
@en
Diabetes prevalence and therap ...... e United States, 1999 to 2006.
@nl
P2093
P50
P1476
Diabetes prevalence and therap ...... e United States, 1999 to 2006.
@en
P2093
Annette W K Tso
Karen S L Lam
Pak-Chung Sham
P304
P356
10.1016/J.AMJMED.2008.09.047
P407
P577
2009-05-01T00:00:00Z